Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
出版年份 2020 全文链接
标题
Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials
作者
关键词
-
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume 184, Issue 1, Pages 23-35
出版商
Springer Science and Business Media LLC
发表日期
2020-08-12
DOI
10.1007/s10549-020-05782-4
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
- (2019) H. S. Rugo et al. BREAST CANCER RESEARCH AND TREATMENT
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer
- (2019) Richard S. Finn et al. CLINICAL CANCER RESEARCH
- Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
- (2018) N C Turner et al. ANNALS OF ONCOLOGY
- First-line ribociclib plus letrozole in postmenopausal women with HR+ , HER2− advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
- (2018) Wolfgang Janni et al. BREAST CANCER RESEARCH AND TREATMENT
- Hormone receptor–positive, HER2-negative metastatic breast cancer: redrawing the lines
- (2018) A. Matutino et al. Current Oncology
- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)
- (2017) M.J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
- (2017) Nicholas C Turner et al. LANCET
- Identifying the potential long-term survivors among breast cancer patients with distant metastasis
- (2016) E. S. Lee et al. ANNALS OF ONCOLOGY
- Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline
- (2016) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib
- (2016) Aleix Prat et al. JAMA Oncology
- Breast Cancer Subtypes Predispose the Site of Distant Metastases
- (2015) Abha Soni et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Clinical implications of the intrinsic molecular subtypes of breast cancer
- (2015) Aleix Prat et al. BREAST
- Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
- (2015) D J A Lobbezoo et al. BRITISH JOURNAL OF CANCER
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of patients with hormone receptor–positive breast cancer with visceral disease: challenges and treatment options
- (2015) Wael Harb Cancer Management and Research
- Absolute Assignment of Breast Cancer Intrinsic Molecular Subtype
- (2014) Eric R. Paquet et al. JNCI-Journal of the National Cancer Institute
- Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers
- (2012) O. Brouckaert et al. ANNALS OF ONCOLOGY
- Biomarkers for the clinical management of breast cancer: International perspective
- (2012) Neill Patani et al. INTERNATIONAL JOURNAL OF CANCER
- Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
- (2011) Su Jin Lee et al. Cancer Research and Treatment
- A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data
- (2009) Marco Bonetti et al. STATISTICS IN MEDICINE
- Subtypes of Breast Cancer Show Preferential Site of Relapse
- (2008) M. Smid et al. CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search